{
    "Rank": 261,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01031446",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "VICC BRE 0949"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA068485",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA068485"
                        },
                        {
                            "SecondaryId": "VU-VICC-BRE-0949"
                        },
                        {
                            "SecondaryId": "IRB# 090673"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Vanderbilt-Ingram Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer",
                "OfficialTitle": "A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "August 2018",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "October 2009"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "December 2011",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "August 2017",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "December 11, 2009",
                "StudyFirstSubmitQCDate": "December 11, 2009",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "December 14, 2009",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "December 6, 2012",
                "ResultsFirstSubmitQCDate": "February 5, 2013",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "March 11, 2013",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "August 3, 2018",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "August 31, 2018",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Ingrid Mayer, MD",
                    "ResponsiblePartyInvestigatorTitle": "Assistant Professor of Medicine; Clinical Director, Breast Cancer Program",
                    "ResponsiblePartyInvestigatorAffiliation": "Vanderbilt-Ingram Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Vanderbilt-Ingram Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving cisplatin and paclitaxel together with everolimus may kill more tumor cells.\n\nPURPOSE: This phase I/II trial is studying the side effects of giving cisplatin and paclitaxel together with everolimus and to see how well it works in treating patients with metastatic breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nSafety profile of cisplatin, paclitaxel, and everolimus (RAD001) in patients with metastatic breast cancer. (Phase I)\nProgression-free survival (Phase II)\n\nSecondary\n\nOverall response rate\nTime to progression\nNumber of patients with worst-grade toxicities Tertiary\nTo determine p53, p63, p73, and phosphatase and tensin homolog (PTEN) levels by immunohistochemistry (IHC).\nTo screen for exon 9 (E542K and E545K), exon 20 (H1047R), and phosphatidylinositol 3-kinase (PI3K) (p110\u03b1) mutations in DNA extracted from paraffin blocks.\nTo correlate IHC results with clinical outcome and with the different subtypes of breast cancer determined by molecular classification (basal-type vs luminal A vs luminal B) based on microarrays of RNA extracted from formalin-fixed paraffin-embedded blocks.\nTo generate microarrays of RNA extracted from fresh-frozen core biopsies (when available) to identify a pretreatment gene signature that mirrors the established p63 and p73 gene signatures that predict response to treatment.\n\nOUTLINE: This is a multicenter study.\n\nPatients receive oral everolimus once daily on days 1-28 and cisplatin IV over 1 hour and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nTumor tissue samples are collected at baseline for correlative studies.\n\nAfter completion of study treatment, patients are followed up at 4 weeks."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IV breast cancer",
                        "Human epidermal growth factor (HER2)-negative breast cancer",
                        "triple-negative breast cancer",
                        "hormone-resistant breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1",
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "55",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Treatment",
                            "ArmGroupType": "Experimental",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: cisplatin",
                                    "Drug: everolimus",
                                    "Drug: paclitaxel",
                                    "Other: laboratory biomarker analysis"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "cisplatin",
                            "InterventionDescription": "Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Treatment"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "everolimus",
                            "InterventionDescription": "Taken daily by mouth.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Treatment"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "paclitaxel",
                            "InterventionDescription": "Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Treatment"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Other",
                            "InterventionName": "laboratory biomarker analysis",
                            "InterventionDescription": "Blood collection",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Treatment"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer",
                            "PrimaryOutcomeDescription": "The recommended dose for the Phase II trial will be the most prevalent dose delivered per week in Phase I that allows for safe and feasible administration of the medications.The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 or more of 3 patients experience dose-limiting toxicity (DLT) during the initial cycle of therapy. DLTs include Common Toxicity Criteria (CTC) Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 x 10 9/L for > 5 days), febrile neutropenia (ANC < 1.0 x 10 0/L with fever > 38.5 degrees Centigrade) or documented infection associated with Grade 3-4 neutropenia, CTC Grade 4 thrombocytopenia < 25 x 10 9/L or CTC Grade 3 < 50-25 x 10 9/L thrombocytopenia with bleeding, and Grade 3-4 non-hematologic toxicity despite symptomatic therapy.",
                            "PrimaryOutcomeTimeFrame": "at 8 weeks"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Maximum Feasible Dose in mg of RAD001 (Everolimus)for Women With Metastatic Breast Cancer",
                            "PrimaryOutcomeDescription": "The recommended dose for the Phase II trial will be the most prevalent dose delivered per day in Phase I that allows for safe and feasible administration the medication. The MTD is defined as the dose preceding that at which 2 or more of 3 patients experience dose-limiting toxicity (DLT) during the initial cycle of therapy. DLTs include Common Toxicity Criteria (CTC) Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 x 10 9/L for > 5 days), febrile neutropenia (ANC < 1.0 x 10 0/L with fever > 38.5 degrees Centigrade) or documented infection associated with Grade 3-4 neutropenia, CTC Grade 4 thrombocytopenia < 25 x 10 9/L or CTC Grade 3 < 50-25 x 10 9/L thrombocytopenia with bleeding, and Grade 3-4 non-hematologic toxicity despite symptomatic therapy",
                            "PrimaryOutcomeTimeFrame": "at 8 weeks"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Patients With Progression-free Survival",
                            "PrimaryOutcomeDescription": "Patients who had not experienced disease progression and who were alive at 6 months after study entry",
                            "PrimaryOutcomeTimeFrame": "at 6 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Patients With Overall Response",
                            "SecondaryOutcomeDescription": "Per Response Evaluation Criteria in Solid Tumor (RECIST) criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions",
                            "SecondaryOutcomeTimeFrame": "every 12 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Time to Progression",
                            "SecondaryOutcomeDescription": "Duration in months from date on-study to date patient exhibited progressive disease",
                            "SecondaryOutcomeTimeFrame": "Up to 64 weeks"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Time to Progression in Patients With Metastatic Basal-like Breast Cancer.",
                            "SecondaryOutcomeDescription": "Median duration in months from on-study to disease progression in patients with metastatic basal-like breast cancer. All patients with basal-like breast cancer are negative for estrogen, progesterone, and human epidermal growth factor (HER2) receptors.",
                            "SecondaryOutcomeTimeFrame": "Up to 64 weeks"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically confirmed invasive mammary carcinoma\n\nStage IV disease\nBasal-like disease (triple-negative, hormone-refractory, HER2-negative)\nNo locally recurrent breast cancer\n\nNo symptomatic brain metastases\n\nPatients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers\nPatients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers\n\nPATIENT CHARACTERISTICS:\n\nPre- or post-menopausal\nEuropean Cooperative Oncology Group (ECOG) performance status 0-1\nLife expectancy \u2265 6 months\nAbsolute neutrophil count (ANC) \u2265 1,000/mm^3\nPlatelet count \u2265 100,000/mm^3\nCreatinine \u2264 1.5 times upper limit of normal (ULN)\n\nTotal bilirubin \u2264 1.5 times ULN (\u2264 3 times ULN in the presence of liver metastasis)\n\nDirect bilirubin will be measured in patients with Gilbert syndrome\nserum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) \u2264 1.5 times ULN (\u2264 3 times ULN in the presence of liver metastasis)\nAlkaline phosphatase \u2264 3 times ULN (in the presence of liver metastasis)\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective barrier contraception during and for 3 months after completion of study treatment\nAble to swallow and retain oral medication\nNo malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel\n\nNo concurrent uncontrolled illness including, but not limited to, any of the following:\n\nOngoing or active infection requiring parenteral antibiotics\nImpaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)\nNew York Heart Association class III-IV congestive heart failure\nUnstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months\nUncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)\nClinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0])\nUncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)\nPsychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary\nNo symptomatic neuropathy \u2265 grade 2\nNo other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ\nNo hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies\nNo history of hepatitis B or C\n\nPRIOR CONCURRENT THERAPY:\n\nSee Disease Characteristics\nRecovered from prior therapy\nPrior total cumulative life-time dose of doxorubicin \u2264 360 mg/m^2 or epirubicin \u2264 640 mg/m^2\nNo more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)\nAt least 2 weeks since prior investigational drugs\nAt least 14 days since prior and no concurrent herbal or dietary supplements\nAt least 14 days since prior and no concurrent CYP3A4 inducers\nAt least 7 days since prior and no concurrent CYP3A4 inhibitors\nConcurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry\nNo other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, biologic therapy)",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Ingrid Mayer, MD",
                            "OverallOfficialAffiliation": "Vanderbilt-Ingram Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Erlanger Cancer Center at Erlanger Hospital - Baroness",
                            "LocationCity": "Chattanooga",
                            "LocationState": "Tennessee",
                            "LocationZip": "37403",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "West Tennessee Cancer Center at Jackson-Madison County General Hospital",
                            "LocationCity": "Jackson",
                            "LocationState": "Tennessee",
                            "LocationZip": "38301",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Baptist Regional Cancer Center at Baptist Riverside",
                            "LocationCity": "Knoxville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37901",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Vanderbilt-Ingram Cancer Center",
                            "LocationCity": "Nashville",
                            "LocationState": "Tennessee",
                            "LocationZip": "37232-6838",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowPreAssignmentDetails": "Fifty-seven patients consented for this study, two were determined ineligible to participate.",
                "FlowRecruitmentDetails": "This study opened to accrual in October 2009 and ran to June 2011.",
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "RAD001 and Cisplatin and Pacletaxel",
                            "FlowGroupDescription": "RAD001 (Everolimus) by mouth once a day. Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. One cycle = 4 weeks. All patients began at the same dose level of the study drugs with no de-escalation of dose, thus results for Phase I and II were combined"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "55"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "0"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "55"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Disease Progression",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "38"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Adverse Event",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "9"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Physician Decision",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "4"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Withdrawal by Subject",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "3"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowDropWithdrawType": "Still on treatment",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "1"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "RAD001 Cisplatin Paclitaxel",
                            "BaselineGroupDescription": "RAD001 (Everolimus) by mouth once a day. Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. One cycle = 4 weeks."
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "55"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Categorical",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "<=18 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Between 18 and 65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "47"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": ">=65 years",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Mean",
                            "BaselineMeasureDispersionType": "Standard Deviation",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "52",
                                                                "BaselineMeasurementSpread": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "54"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "55"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer",
                            "OutcomeMeasureDescription": "The recommended dose for the Phase II trial will be the most prevalent dose delivered per week in Phase I that allows for safe and feasible administration of the medications.The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 or more of 3 patients experience dose-limiting toxicity (DLT) during the initial cycle of therapy. DLTs include Common Toxicity Criteria (CTC) Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 x 10 9/L for > 5 days), febrile neutropenia (ANC < 1.0 x 10 0/L with fever > 38.5 degrees Centigrade) or documented infection associated with Grade 3-4 neutropenia, CTC Grade 4 thrombocytopenia < 25 x 10 9/L or CTC Grade 3 < 50-25 x 10 9/L thrombocytopenia with bleeding, and Grade 3-4 non-hematologic toxicity despite symptomatic therapy.",
                            "OutcomeMeasurePopulationDescription": "Patients enrolled to determine the safety profile and recommended doses of cisplatin + paclitaxel + everolimus (RAD001) in women with metastatic breast cancer",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "mg/m2",
                            "OutcomeMeasureTimeFrame": "at 8 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "RAD001 and Cisplatin and Paclitazel",
                                        "OutcomeGroupDescription": "Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "3"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Cisplatin",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "25"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Paclitaxel",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "80"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Maximum Feasible Dose in mg of RAD001 (Everolimus)for Women With Metastatic Breast Cancer",
                            "OutcomeMeasureDescription": "The recommended dose for the Phase II trial will be the most prevalent dose delivered per day in Phase I that allows for safe and feasible administration the medication. The MTD is defined as the dose preceding that at which 2 or more of 3 patients experience dose-limiting toxicity (DLT) during the initial cycle of therapy. DLTs include Common Toxicity Criteria (CTC) Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 x 10 9/L for > 5 days), febrile neutropenia (ANC < 1.0 x 10 0/L with fever > 38.5 degrees Centigrade) or documented infection associated with Grade 3-4 neutropenia, CTC Grade 4 thrombocytopenia < 25 x 10 9/L or CTC Grade 3 < 50-25 x 10 9/L thrombocytopenia with bleeding, and Grade 3-4 non-hematologic toxicity despite symptomatic therapy",
                            "OutcomeMeasurePopulationDescription": "Patients enrolled to determine the safety profile and recommended dose of cisplatin + RAD001 + paclitaxel in women with metastatic breast cancer",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "mg",
                            "OutcomeMeasureTimeFrame": "at 8 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "RAD001 and Cisplatin and Paclitaxel",
                                        "OutcomeGroupDescription": "Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks"
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "3"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Patients With Overall Response",
                            "OutcomeMeasureDescription": "Per Response Evaluation Criteria in Solid Tumor (RECIST) criteria v. 1.0: measurable lesions: complete response (CR) disappearance of target lesions, partial response (PR) > 30% decrease in the sum of the longest diameter (LD) of target lesions, progressive disease (PD) > 20% increase in the sum of the LD of target lesions or appearance of new lesions, stable disease (SD) neither sufficient decrease nor increase of the sum of smallest sum of the LD of target lesions",
                            "OutcomeMeasurePopulationDescription": "Patients for whom an overall response could be measured. Four patients were not evaluable due to: withdrew after beginning treatment (1) and not evaluable due to only 1 cycle of treatment (3).",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "every 12 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "RAD001 and Cisplatin and Paclitaxel",
                                        "OutcomeGroupDescription": "Patients receive cisplatin IV 25 mg/m2, paclitaxel IV 80 mg/m2 (both drugs once weekly for 3 weeks followed by 1 week of rest), and RAD001 5 mg by mouth daily. 1 cycle = 4 weeks."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "51"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeClassTitle": "Complete Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Partial Response",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Progressive Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeClassTitle": "Stable Disease",
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "27"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Time to Progression",
                            "OutcomeMeasureDescription": "Duration in months from date on-study to date patient exhibited progressive disease",
                            "OutcomeMeasurePopulationDescription": "Patients who were available for determination of duration of time to progressive disease. Time to progression is unknown for 8 Phase II patients due to: on-treatment (1), toxicity (3), withdrew after beginning treatment (1), and no progression (3)",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "Full Range",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "Up to 64 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "RAD001 and Cisplatin and Paclitaxel",
                                        "OutcomeGroupDescription": "Patients receive cisplatin IV 25 mg/m2, paclitaxel IV 80 mg/m2 (both drugs once weekly for 3 weeks followed by 1 week of rest), and RAD001 5 mg by mouth daily. 1 cycle = 4 weeks."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "47"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "4.0",
                                                                "OutcomeMeasurementLowerLimit": "0.4",
                                                                "OutcomeMeasurementUpperLimit": "23.0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Patients With Progression-free Survival",
                            "OutcomeMeasureDescription": "Patients who had not experienced disease progression and who were alive at 6 months after study entry",
                            "OutcomeMeasurePopulationDescription": "Patient who received the study drugs. Four patients were not available for measurement of progression at 6 months: toxicity (3), withdrew after beginning treatment (1)",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "at 6 months",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "RAD001 and Cisplatin and Paclitaxel",
                                        "OutcomeGroupDescription": "Patients receive cisplatin IV 25 mg/m2, paclitaxel IV 80 mg/m2 (both drugs once weekly for 3 weeks followed by 1 week of rest), and RAD001 5 mg by mouth daily. 1 cycle = 4 weeks."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "51"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "21",
                                                                "OutcomeMeasurementLowerLimit": "0",
                                                                "OutcomeMeasurementUpperLimit": "23"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "OutcomeMeasureType": "Secondary",
                            "OutcomeMeasureTitle": "Time to Progression in Patients With Metastatic Basal-like Breast Cancer.",
                            "OutcomeMeasureDescription": "Median duration in months from on-study to disease progression in patients with metastatic basal-like breast cancer. All patients with basal-like breast cancer are negative for estrogen, progesterone, and human epidermal growth factor (HER2) receptors.",
                            "OutcomeMeasurePopulationDescription": "Patients who are negative for estrogen, progesterone and HER2 receptors. Time to progression was not determined for 5 patients in this group: toxicity (2), withdrew after beginning treatment (1), no progression (1), and on-treatment (1).",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Median",
                            "OutcomeMeasureDispersionType": "Full Range",
                            "OutcomeMeasureUnitOfMeasure": "months",
                            "OutcomeMeasureTimeFrame": "Up to 64 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "RAD001 and Cisplatin and Paclitaxel",
                                        "OutcomeGroupDescription": "Patients receive cisplatin IV 25 mg/m2, paclitaxel IV 80 mg/m2 (both drugs once weekly for 3 weeks followed by 1 week of rest), and RAD001 5 mg by mouth daily. 1 cycle = 4 weeks."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "31"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "4.0",
                                                                "OutcomeMeasurementLowerLimit": "0.4",
                                                                "OutcomeMeasurementUpperLimit": "23.0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "RAD001 and Cisplatin and Paclitaxel",
                            "EventGroupDescription": "RAD001 (Everolimus) by mouth once a day. Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. One cycle = 4 weeks.",
                            "EventGroupSeriousNumAffected": "9",
                            "EventGroupSeriousNumAtRisk": "55",
                            "EventGroupOtherNumAffected": "55",
                            "EventGroupOtherNumAtRisk": "55"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "pain-abdomen",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "6",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "death not associated with CTCAE term-disease progression NOS",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Left maxillary odontogenic abscess and cellulitis",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "glucose, serum-low (hypoglycemia)",
                            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "pain-back",
                            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "neutrophils",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "4",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "leukocytes",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "platelets",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "cholecystitis",
                            "SeriousEventOrganSystem": "Hepatobiliary disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "malignant pleural effusion",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "2",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "dyspnea",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "6",
                                        "SeriousEventStatsNumAffected": "5",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "infection with unknown ANC-mucosititis",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "infection with unknown ANC-wound, methicillin-resistant Staphylococcus aureus",
                            "SeriousEventOrganSystem": "Infections and infestations",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "febrile neutropenia, ANC < 1.0 x 10e9L, fever \u2265 38.5 degrees Celsius",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "fever in absence of neutropenia w/ neutropenia defined as ANC < 1.0 x 10e9L",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "4",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "diarrhea",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "nausea",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "vomiting",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "thromboembolism (vascular access-related)",
                            "SeriousEventOrganSystem": "Vascular disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "enteritis, small bowel",
                            "SeriousEventOrganSystem": "Gastrointestinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "edema, facial",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "infection with unknown ANC-urinary tract NOS",
                            "SeriousEventOrganSystem": "Renal and urinary disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "calcium, serum-high (hypercalcemia)",
                            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "hydrocephalus",
                            "SeriousEventOrganSystem": "Nervous system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "pain-headache",
                            "SeriousEventOrganSystem": "Nervous system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "ventricular tachycardia",
                            "SeriousEventOrganSystem": "Cardiac disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "pain-right-sided thorax (non-cardiac)",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "cough",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "pneumonia",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "anemia",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "thrombocytopenia",
                            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "2",
                                        "SeriousEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "albumin, serum-low",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "alkaline phosphatase",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "51",
                                        "OtherEventStatsNumAffected": "23",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "allergic reaction\\hypersensitivity (including drug fever)",
                            "OtherEventOrganSystem": "Immune system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "allergy/immunology-other",
                            "OtherEventOrganSystem": "Immune system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "ALT, SGPT (serum glutamic pyruvic transaminase)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "44",
                                        "OtherEventStatsNumAffected": "22",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "anorexia",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "18",
                                        "OtherEventStatsNumAffected": "12",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "AST, SGOT (serum glutamic oxaloacetic transaminase)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "18",
                                        "OtherEventStatsNumAffected": "14",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "calcium, serum-high (hypercalcemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "cholesterol, serum-high (hypercholesteremia",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "26",
                                        "OtherEventStatsNumAffected": "17",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "constipation",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "21",
                                        "OtherEventStatsNumAffected": "18",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "constitutional symptoms-other",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "162",
                                        "OtherEventStatsNumAffected": "19",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "cough",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "12",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "creatinine",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dermatology/skin-other",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "21",
                                        "OtherEventStatsNumAffected": "13",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "diarrhea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "28",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dizziness",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "dyspnea",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "edema limb",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "17",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "45",
                                        "OtherEventStatsNumAffected": "32",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "gastrointestinal-other",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "glucose, serum-high (hyperglycemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "76",
                                        "OtherEventStatsNumAffected": "33",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hair loss/alopecia (scalp or body)",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "heartburn/dyspepsia",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hemoglobin",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "182",
                                        "OtherEventStatsNumAffected": "52",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "hemorrhage, pumonary/upper respiratory-nose",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "infection-other",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "infection with normal ANC or grade 1 or 2 neutrophils-urinary tract NOS",
                            "OtherEventOrganSystem": "Renal and urinary disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "insomnia",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "9",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "leukocytes (total WBC)",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "141",
                                        "OtherEventStatsNumAffected": "33",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "nausea",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "44",
                                        "OtherEventStatsNumAffected": "34",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "neurology-other",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "28",
                                        "OtherEventStatsNumAffected": "12",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "neuropathy-sensory",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "29",
                                        "OtherEventStatsNumAffected": "16",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "neutrophils/granulocytes (ANC/AGC)",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "77",
                                        "OtherEventStatsNumAffected": "28",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain back",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-breast",
                            "OtherEventOrganSystem": "Reproductive system and breast disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-chest wall",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-extremity-limb",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-head/headache",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "12",
                                        "OtherEventStatsNumAffected": "11",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-other",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "34",
                                        "OtherEventStatsNumAffected": "22",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "platelets",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "85",
                                        "OtherEventStatsNumAffected": "39",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "potassium-serum-low (hypokalemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "33",
                                        "OtherEventStatsNumAffected": "20",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pulmonary/upper respiratory-other",
                            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "9",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "rash acne/acneiform",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "8",
                                        "OtherEventStatsNumAffected": "7",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "sodium, serum-low (hyponatremia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "25",
                                        "OtherEventStatsNumAffected": "14",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "taste alteration (dysgeusia)",
                            "OtherEventOrganSystem": "Nervous system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "7",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "tinnitus",
                            "OtherEventOrganSystem": "Ear and labyrinth disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "triglyceride, serum-high (hypertriglyceridemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "17",
                                        "OtherEventStatsNumAffected": "15",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "18",
                                        "OtherEventStatsNumAffected": "12",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-joint",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "magnesium, serum-low (hypomagnesemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "11",
                                        "OtherEventStatsNumAffected": "8",
                                        "OtherEventStatsNumAtRisk": "52"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "metabolic/laboratory-other",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "145",
                                        "OtherEventStatsNumAffected": "19",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "blood/bone marrow-other",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "10",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "calcium, serum-low (hypocalcemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "30",
                                        "OtherEventStatsNumAffected": "14",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "potassium, serum-high (hyperkalemia)",
                            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "mucositis/stomatitis (clinical exam)-oral cavity",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "12",
                                        "OtherEventStatsNumAffected": "10",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "mucositis/stomatitis (functional/symptomatic)-oral cavity",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "6",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "nail changes",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pruritis/itching",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "rash/desquamation",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "depression",
                            "OtherEventOrganSystem": "Psychiatric disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "infection with normal ANC or Grade 1 or 2 neutrophils-nails",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "infection with normal ANC or Grade 1 or 2 neutrophils-upper airway NOS",
                            "OtherEventOrganSystem": "Infections and infestations",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "6",
                                        "OtherEventStatsNumAffected": "5",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "lymphatics-other",
                            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "3",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain-neck",
                            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "4",
                                        "OtherEventStatsNumAffected": "3",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "pain-abdomen NOS",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "5",
                                        "OtherEventStatsNumAffected": "4",
                                        "OtherEventStatsNumAtRisk": "55"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Ingrid A. Mayer, MD",
                    "PointOfContactOrganization": "Vanderbilt-Ingram Cancer Center",
                    "PointOfContactEMail": "ingrid.mayer@vanderbilt.edu",
                    "PointOfContactPhone": "615-936-2033"
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M30063",
                            "ConditionBrowseLeafName": "Triple Negative Breast Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000017239",
                            "InterventionMeshTerm": "Paclitaxel"
                        },
                        {
                            "InterventionMeshId": "D000068338",
                            "InterventionMeshTerm": "Everolimus"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000972",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Phytogenic"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050257",
                            "InterventionAncestorTerm": "Tubulin Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000050256",
                            "InterventionAncestorTerm": "Antimitotic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000050258",
                            "InterventionAncestorTerm": "Mitosis Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000091203",
                            "InterventionAncestorTerm": "MTOR Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000007166",
                            "InterventionAncestorTerm": "Immunosuppressive Agents"
                        },
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M19227",
                            "InterventionBrowseLeafName": "Paclitaxel",
                            "InterventionBrowseLeafAsFound": "Months",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M5872",
                            "InterventionBrowseLeafName": "Cisplatin",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M231",
                            "InterventionBrowseLeafName": "Albumin-Bound Paclitaxel",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9479",
                            "InterventionBrowseLeafName": "Hormones",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M11590",
                            "InterventionBrowseLeafName": "Mitogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M255",
                            "InterventionBrowseLeafName": "Everolimus",
                            "InterventionBrowseLeafAsFound": "Resistance",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M25887",
                            "InterventionBrowseLeafName": "Tubulin Modulators",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25886",
                            "InterventionBrowseLeafName": "Antimitotic Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M21650",
                            "InterventionBrowseLeafName": "Sirolimus",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M352429",
                            "InterventionBrowseLeafName": "Temsirolimus",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2828",
                            "InterventionBrowseLeafName": "MTOR Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9902",
                            "InterventionBrowseLeafName": "Immunosuppressive Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        }
                    ]
                }
            }
        }
    }
}